Bacterial pathogen reduction requires validation under conditions of intended use

Transfusion

Volumn 55, Issue 9, 2015, Pages 2060-2063

  Benjamin, Richard J ^a   Wagner, Stephen J ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; RIBOFLAVIN;

ACINETOBACTER BAUMANNII; APHERESIS; BACILLUS CEREUS; BACTERIAL CLEARANCE; BACTERIAL INFECTION; BACTERIAL SPORE; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BLOOD DONOR; BLOOD SAFETY; ENTEROBACTER CLOACAE; HEPATITIS A VIRUS; HEPATITIS E VIRUS; HUMAN; HUMAN PARVOVIRUS B19; INFECTION PREVENTION; INOCULATION; KLEBSIELLA PNEUMONIAE; PATHOGEN LOAD; PATIENT SAFETY; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET A RADIATION; ULTRAVIOLET RADIATION; DISINFECTION; DONOR SELECTION; MICROBIAL VIABILITY; PROCEDURES;

BACILLUS CEREUS; BLOOD SAFETY; DISINFECTION; DONOR SELECTION; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL VIABILITY;

EID: 84941794004     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13232     Document Type: Review

References (19)

1. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report, Series No. 924 annex 4. Geneva: World Health Organization; 2004.
2. Corash L., Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis. Expert Rev Hematol 2011; 4: 509-25.
3. Benjamin RJ., Pathogen inactivation-defining "adequate" bacterial protection. ISBT Sci Ser 2014; 9: 124-30.
4. Kwon SY, Kim IS, Bae JE, et al., Pathogen inactivation efficacy of Mirasol PRT system and Intercept blood system for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 2014; 107: 254-60.
5. Prowse CV., Component pathogen inactivation: a critical review. Vox Sang 2013; 104: 183-99.
6. Hauser L, Roque-Afonso AM, Beylouné A, et al., Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014; 123: 796-7.
7. Schmidt M, Kapzrak B, Pfeiffer HU, et al., Efficiency of pathogen inactivation system Intercept under experimental conditions [abstract P367]. Vox Sang 2011; 101 Suppl 1: 226.
8. Schmidt M, Hourfar MK, Sireis W, et al., Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion transmitted bacterial strains. Transfusion 2015; 55: 2104-12.
9. Goodrich RP, Gilmour D, Hovenga N, et al., A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-16.
10. Goodrich RP, Edrich RA, Li J, et al., The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
11. Störmer M, Arroyo A, Brachert J, et al., Establishment of the first international repository for transfusion-relevant bacteria reference strains: ISBT working party transfusion-transmitted infectious diseases (WP-TTID), subgroup on bacteria. Vox Sang 2012; 102: 22-31.
12. Schrezenmeier H, Walther-Wenke G, Müller TH, et al., Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47: 644-52.
13. Niu MT, Knippen M, Simmons L, et al., Transfusion-transmitted Klebsiella pneumoniae fatalities, 1995 to 2004. Transfus Med Rev 2006; 20: 149-57.
14. Pearce S, Rowe GP, Field SP., Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus Med 2011; 21: 25-32.
15. Murphy WG, Foley M, Doherty C, et al., Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95: 13-9.
16. Benjamin RJ, McDonald CP., The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines. Transfus Med Rev 2014; 28: 61-71.
17. Nussbaumer W, Allersdorfer D, Grabmer C, et al., Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion 2007; 47: 1125-33.
18. Wagner SJ, Benjamin RJ, Hapip CA, et al., Inactivation of bacteria in apheresis platelets with pathogen reduction performed 24 hours after inoculation [Abstract 4D-S27-06]. Vox Sang 2015; 109 (Suppl. 1): 63.
19. Jacobs MR, Good CE, Lazarus HM, et al., Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis 2008; 46: 1214-20.